Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.91 USD
+0.01 (0.53%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $1.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.91 USD
+0.01 (0.53%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $1.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0% and 15.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Actinium (ATNM) Up on Commercialization Deal With Immedica
by Zacks Equity Research
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Is Apria (APR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apria (APR) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Surging Earnings Estimates Signal Good News for Actinium (ATNM)
by Zacks Equity Research
Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.40, moving -1.04% from the previous trading session.
Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.11, marking a +0.63% move from the previous day.
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.35, marking a +0.78% move from the previous day.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed at $12.01 in the latest trading session, marking a +0.5% move from the prior day.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.82, marking a +0.34% move from the previous day.
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $9.18, moving -1.71% from the previous trading session.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season?
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.